Guides · PeptideU · 9 min read

Survodutide Benefits: What Studies Report

The short answer

Survodutide is an investigational glucagon/GLP-1 dual receptor agonist studied as a prescription medicine, not an approved product in the literature cited here. Randomized phase 2 trials reported greater body-weight reduction than placebo over 46 weeks in adults with overweight or obesity, and higher rates of MASH improvement without worsening fibrosis over 48 weeks. Reviews placed it within the GLP-1-based class. Gastrointestinal adverse events were reported more often than with placebo. Cardiovascular outcome data were absent from the cited set.

What survodutide is, and what the published evidence covers

Survodutide (development code BI 456906) is an investigational once-weekly injectable that activates both the glucagon receptor and the glucagon-like peptide-1 (GLP-1) receptor. It is being developed as a prescription medicine and has been evaluated in randomized controlled trials rather than distributed as a consumer product; a 2026 review of novel GLP-1-based medications for type 2 diabetes and obesity grouped survodutide with other glucagon/GLP-1 dual agonists under clinical investigation (PMID 41054801), and a 2025 systematic review of emerging obesity pharmacotherapies likewise described it among agents in development rather than among approved therapies (PMID 39952695).

This page organizes, by outcome domain, what published studies actually measured and reported. The frame throughout is studied for and reported in studies — not established benefit. Where the available evidence is review-level, indirect, or absent, that is stated plainly. Questions about whether any medicine is appropriate for a given person belong with a prescribing clinician.

Outcome domains at a glance

Domain	Type of evidence cited	Direction reported
Body weight	46-week randomized phase 2 dose-finding trial in adults with overweight or obesity without type 2 diabetes	Greater mean weight reduction than placebo across doses tested (PMID 38330987)
MASH and fibrosis	48-week randomized phase 2 trial in biopsy-confirmed MASH with fibrosis	Higher rates of histologic MASH improvement without worsening fibrosis than placebo (PMID 38847460)
Liver fat and liver enzymes	Phase 2 trial secondary endpoints; systematic review and meta-analysis of GLP-1-based therapies	Reductions reported with active treatment in the pooled literature (PMID 40489581)
Glycemia in type 2 diabetes	Class-level reviews only in this citation set	No dedicated survodutide phase 3 diabetes result cited here (PMID 38843460)
Cardiovascular events	None in this citation set	Not reported in the trials cited here (PMID 42253238)
Tolerability	Both randomized phase 2 trials	Gastrointestinal adverse events more frequent than with placebo (PMID 38330987)

Body weight: what the trials measured

The most detailed published weight data came from a randomized, double-blind, placebo-controlled phase 2 dose-finding trial in adults with a body-mass index of 27 kg/m² or higher without type 2 diabetes, in which researchers assigned participants to weekly subcutaneous survodutide at 0.6 mg, 2.4 mg, 3.6 mg or 4.8 mg, or placebo, for 46 weeks with a dose-escalation period followed by maintenance (PMID 38330987). In that study, the mean percentage change in body weight at week 46 was approximately −6.2% at 0.6 mg, −12.5% at 2.4 mg, −13.2% at 3.6 mg and −14.9% at 4.8 mg, compared with about −2.8% with placebo, with larger reductions at the higher doses tested (PMID 38330987).

A 2026 report in The New England Journal of Medicine described once-weekly survodutide in adults with obesity at the phase 3 stage of development, moving the program beyond dose-finding into a larger confirmatory setting (PMID 42253238). Narrative and systematic reviews of obesity pharmacotherapy have discussed dual glucagon/GLP-1 receptor agonism as one of several incretin-based strategies being tested against single-receptor agonists, without concluding that any one agent is superior for all populations (PMID 39952695, PMID 40865172).

How to read percentage figures

Percentages reported in a trial describe group averages under a defined protocol, with scheduled escalation, monitoring and study visits; individual results varied around those means, and the 46-week horizon of the dose-finding study does not describe what happens over longer periods (PMID 38330987).

Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.

Try it free

Liver outcomes: MASH and fibrosis

A phase 2 randomized trial published in 2024 enrolled adults with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis stages F1 to F3, assigning weekly survodutide at 2.4 mg, 4.8 mg or 6.0 mg or placebo for 48 weeks, with the primary endpoint of histologic improvement in MASH without worsening of fibrosis (PMID 38847460). Researchers reported that the primary endpoint was met in roughly 47%, 62% and 43% of participants in the 2.4 mg, 4.8 mg and 6.0 mg groups respectively, compared with about 14% with placebo, and also reported greater reductions in liver fat content with survodutide than with placebo (PMID 38847460).

At the review level, a 2025 systematic review and meta-analysis of GLP-1-based therapies in metabolic dysfunction-associated steatotic liver disease and MASH pooled trials of incretin-based agents and reported improvements in hepatic steatosis and related measures relative to comparators (PMID 40489581). A 2025 network meta-analysis compared pharmacological options for MASH resolution and fibrosis regression across trials and ranked agents on those two histologic endpoints, an approach that relies on indirect comparison rather than head-to-head testing (PMID 39903735). Reviews of the MASH treatment landscape have placed GLP-1, GIP/GLP-1 and glucagon/GLP-1 receptor agonists among the mechanisms under active study, while noting that histologic endpoints are surrogate markers rather than clinical events such as decompensation or death (PMID 39735270, PMID 40590228).

Glycemic outcomes

The published phase 2 obesity trial described above enrolled adults without type 2 diabetes, so it does not speak to glycemic control in a diabetic population (PMID 38330987). Broad reviews of GLP-1 medicines for type 2 diabetes and obesity have summarized efficacy and safety across the class and discussed how dual-agonist candidates are being positioned within it (PMID 38843460, PMID 41054801). No dedicated phase 3 glycemic efficacy result for survodutide in type 2 diabetes appears among the publications cited on this page.

Tracking research? Log entries with dates, lots and notes — records, never plans.

Get the app

Body composition and lean mass

Body-composition questions are frequently raised about any medicine that produces substantial weight loss. A 2024 review in Metabolism examined how large reductions in body weight relate to fat-free mass, skeletal muscle, bone and hematopoietic measures, and discussed the pharmacologic goal of reducing fat mass while limiting lean-tissue loss (PMID 39481534). That discussion is class-level and conceptual; it is not a survodutide-specific body-composition trial, and the cited survodutide trials reported body weight and histology rather than detailed lean-mass endpoints (PMID 38330987, PMID 38847460).

Claimed benefits where the cited evidence is thin or absent

Cardiovascular event reduction: the publications cited here consist of phase 2 trials, a phase 3 obesity report and reviews; none of them reported a completed cardiovascular outcomes trial for survodutide (PMID 42253238, PMID 41054801).
Cirrhosis and hard liver endpoints: the phase 2 MASH trial used histologic endpoints over 48 weeks in F1–F3 fibrosis and did not report long-term clinical liver events (PMID 38847460).
Sleep apnea, joint pain, fertility, cognition, longevity: no outcomes in these domains were reported in the survodutide trials cited on this page (PMID 38330987).
Muscle building or athletic performance: not an endpoint in the cited trials; the only cited lean-mass discussion is a review of weight-loss physiology generally (PMID 39481534).

Want the full course? Every compound, evidence-graded and cited, inside PeptideU.

Start learning free

Tolerability and Adverse Events: What Studies Report

In the 46-week phase 2 obesity trial, researchers reported that adverse events occurred more often with survodutide than placebo and were predominantly gastrointestinal, with nausea, vomiting and diarrhea most commonly described and discontinuations for adverse events more frequent at higher doses (PMID 38330987). In the 48-week MASH trial, nausea, diarrhea and vomiting were likewise the most frequently reported adverse events and occurred more often with survodutide than with placebo (PMID 38847460). Class-level reviews of GLP-1-based medicines have described gastrointestinal intolerance as the dominant tolerability issue across incretin agents, typically most prominent during dose escalation (PMID 38843460).

Regulatory and access context

Survodutide is described in the cited literature as an investigational prescription medicine evaluated in randomized trials, not as a supplement, consumer product or research chemical for personal use (PMID 39952695). Any decision about prescription weight-management or liver-directed therapy — including whether a trial-stage agent is relevant, available, or appropriate — is a matter for a licensed prescribing clinician who can weigh a person's full medical history against published trial evidence such as the phase 2 and phase 3 reports summarized above (PMID 42253238).

Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.

Try it free

Limitations readers should keep in view

Trial populations were selected. The obesity dose-finding trial enrolled adults with BMI ≥27 kg/m² without type 2 diabetes, so its results do not automatically transfer to other groups (PMID 38330987).
Durations were short relative to chronic disease. The cited randomized evidence spanned 46 and 48 weeks (PMID 38330987, PMID 38847460).
Cross-drug comparisons were mostly indirect. Rankings in network meta-analyses derive from pooled indirect comparisons rather than head-to-head trials (PMID 39903735).
Surrogate endpoints dominate. Percentage weight change and liver histology are intermediate measures, a point emphasized in reviews of the MASH field (PMID 40590228).

This page is for educational purposes only and is not medical advice; consult a licensed physician or qualified healthcare professional about any medical condition, medication or treatment decision. Nothing above describes a protocol, and no outcome described in these studies should be expected for any individual.

References

Frequently asked questions

What outcomes has survodutide actually been studied for?▾

Published randomized evidence focused on two domains. A 46-week phase 2 dose-finding trial measured percentage body-weight change in adults with overweight or obesity without type 2 diabetes (PMID 38330987), and a 48-week phase 2 trial measured histologic improvement in MASH without worsening of fibrosis in adults with biopsy-confirmed disease (PMID 38847460). A 2026 report described once-weekly dosing in adults with obesity (PMID 42253238).

How much weight change did the phase 2 trial report?▾

Researchers reported mean body-weight changes at week 46 of approximately −6.2%, −12.5%, −13.2% and −14.9% with weekly survodutide at 0.6, 2.4, 3.6 and 4.8 mg respectively, versus about −2.8% with placebo (PMID 38330987). Those are group averages from a monitored trial with scheduled dose escalation, not individual expectations, and reviews stress class-wide variability (PMID 39952695).

What did the liver trial report about MASH and fibrosis?▾

In the 48-week phase 2 MASH trial, the primary endpoint of MASH improvement without worsening fibrosis was met in roughly 47%, 62% and 43% of the 2.4, 4.8 and 6.0 mg groups versus about 14% with placebo, with greater liver-fat reduction than placebo (PMID 38847460). Histology is a surrogate endpoint, not a clinical liver event (PMID 40590228).

What adverse events did studies report?▾

Gastrointestinal effects dominated. The obesity dose-finding trial reported nausea, vomiting and diarrhea most often, with more adverse-event discontinuations at higher doses (PMID 38330987). The MASH trial likewise reported nausea, diarrhea and vomiting more frequently with survodutide than placebo (PMID 38847460). Class reviews describe gastrointestinal intolerance as the main tolerability issue across incretin-based medicines (PMID 38843460).

Is there evidence survodutide reduces heart attacks or strokes?▾

Not in the literature summarized here. The cited publications comprise phase 2 trials, a phase 3 obesity report and reviews, none of which reported completed cardiovascular outcome trial results for survodutide (PMID 42253238, PMID 41054801). Claims about cardiovascular event reduction therefore go beyond what these studies measured, and such questions belong with a prescribing clinician.

Does survodutide preserve muscle during weight loss?▾

The cited survodutide trials reported body weight and liver histology rather than detailed lean-mass endpoints (PMID 38330987, PMID 38847460). A 2024 review discussed how substantial weight loss relates to fat-free mass, muscle and bone, and the pharmacologic aim of limiting lean-tissue loss (PMID 39481534), but that is class-level discussion, not survodutide-specific body-composition data.

Is survodutide an approved medicine?▾

In the publications cited here it is described as an investigational prescription medicine evaluated in randomized trials, grouped with other glucagon/GLP-1 dual agonists in development rather than among approved therapies (PMID 39952695, PMID 41054801). Availability, suitability and regulatory status change over time, so a licensed prescribing clinician is the appropriate source for current information.

The PeptideU app

Track it. Calculate it. Actually understand it.

Research trackerLog every entry with dates, lots and notes — records, never plans.

CalculatorsReconstitution, units and dilution maths without the guesswork.

The UniversityEvery compound explained, evidence-graded, cited to the literature.

Get started freePeptideU Premium — $9.99/mo for the full curriculum, advanced tracking & giveaways

Download on theApp Store — Free Get it onGoogle Play

References

Keep learning

18+ · Educational purposes only
This page summarises published research for education — it is not medical advice, and nothing here is a recommendation to use, purchase, or dose any substance. Study parameters described are what researchers reported, not instructions. Consult a qualified clinician before any health decision.